Skip to main content
NCBI home page
Gut logoLink to Gut
. 1997 Mar;40(3):344–349. doi: 10.1136/gut.40.3.344

Effects of sulindac on sporadic colorectal adenomatous polyps.

N Matsuhashi 1, A Nakajima 1, Y Fukushima 1, Y Yazaki 1, T Oka 1
PMCID: PMC1027084  PMID: 9135523

Abstract

BACKGROUND: Although sulindac is known to cause regression of colorectal adenomatous polyps in familial adenomatous polyposis, less is known about the effect of sulindac on sporadic adenomas. The precise mechanisms of these effects also remain to be determined. AIMS: Sulindac was given to patients with sporadic colorectal adenomatous polyps to evaluate its effects on them, and histological analysis was performed to elucidate the mechanism of the polyp regression, as well the kind of adenomatous polys that are susceptible to the agent. SUBJECTS: 20 adenomatous polyps in 15 patients were studied. METHODS: Sulindac (300 mg daily) was given for four months, followed by colonoscopy with removal of the residual polyps. Polyp size, degree of atypia, inflammatory cell infiltration in the polyps, and immunostaining for mutant p53 product were evaluated before and after treatment. RESULTS: 13 of the 20 polyps shrank or disappeared. Patient sex, polyp location, size, degree of atypia, or p53 mutation did not affect the response, but polyps in older patients were more sensitive to sulindac. The degree of atypia or inflammatory cell infiltration was not affected by the treatment. A polyp containing a focal cancer was unresponsive. CONCLUSIONS: Sulindac can cause regression of sporadic colorectal adenomatous polyps.

Full text

PDF
344

Images in this article

345Image
on p.345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Salem T., Ali Z. S., Qassab M. Skin cancers in xeroderma pigmentosum: response to indomethacin and steroids. Lancet. 1980 Aug 2;2(8188):264–265. doi: 10.1016/s0140-6736(80)90154-3. [DOI] [PubMed] [Google Scholar]
  2. Bennett A., Houghton J., Leaper D. J., Stamford I. F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins. 1979 Feb;17(2):179–191. doi: 10.1016/0090-6980(79)90037-6. [DOI] [PubMed] [Google Scholar]
  3. Charneau J., D'Aubigny N., Burtin P., Person B., Boyer J. Micropolypes rectaux après colectomie totale pour polypose familiale. Efficacité du sulindac. Gastroenterol Clin Biol. 1990;14(2):153–157. [PubMed] [Google Scholar]
  4. Craven P. A., DeRubertis F. R. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis. 1992 Apr;13(4):541–546. doi: 10.1093/carcin/13.4.541. [DOI] [PubMed] [Google Scholar]
  5. Debinski H. S., Trojan J., Nugent K. P., Spigelman A. D., Phillips R. K. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet. 1995 Apr 1;345(8953):855–856. [PubMed] [Google Scholar]
  6. DuBois R. N. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology. 1995 Apr;108(4):1310–1314. doi: 10.1016/0016-5085(95)90235-x. [DOI] [PubMed] [Google Scholar]
  7. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  8. Friend W. G. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am Fam Physician. 1990 Mar;41(3):891–894. [PubMed] [Google Scholar]
  9. Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6;328(18):1313–1316. doi: 10.1056/NEJM199305063281805. [DOI] [PubMed] [Google Scholar]
  10. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Willett W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994 Aug 15;121(4):241–246. doi: 10.7326/0003-4819-121-4-199408150-00001. [DOI] [PubMed] [Google Scholar]
  11. Gonzaga R. A., Lima F. R., Carneiro S., Maciel J., Amarante Júnior M. Sulindac treatment for familial polyposis coli. Lancet. 1985 Mar 30;1(8431):751–751. doi: 10.1016/s0140-6736(85)91286-3. [DOI] [PubMed] [Google Scholar]
  12. Greenberg E. R., Baron J. A., Freeman D. H., Jr, Mandel J. S., Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 1993 Jun 2;85(11):912–916. doi: 10.1093/jnci/85.11.912. [DOI] [PubMed] [Google Scholar]
  13. Hial V., De Mello M. C., Horakova Z., Beaven M. A. Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. J Pharmacol Exp Ther. 1977 Aug;202(2):446–454. [PubMed] [Google Scholar]
  14. Hial V., Horakova Z., Shaff F. E., Beaven M. A. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol. 1976 Jun;37(2):367–376. doi: 10.1016/0014-2999(76)90044-3. [DOI] [PubMed] [Google Scholar]
  15. Hirata K., Itoh H., Ohsato K. Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Report of two cases. Dis Colon Rectum. 1994 Sep;37(9):943–946. doi: 10.1007/BF02052603. [DOI] [PubMed] [Google Scholar]
  16. Hixson L. J., Earnest D. L., Fennerty M. B., Sampliner R. E. NSAID effect on sporadic colon polyps. Am J Gastroenterol. 1993 Oct;88(10):1652–1656. [PubMed] [Google Scholar]
  17. Kune G. A., Kune S., Watson L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988 Aug 1;48(15):4399–4404. [PubMed] [Google Scholar]
  18. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991 Sep;101(3):635–639. doi: 10.1016/0016-5085(91)90519-q. [DOI] [PubMed] [Google Scholar]
  19. Ladenheim J., Garcia G., Titzer D., Herzenberg H., Lavori P., Edson R., Omary M. B. Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995 Apr;108(4):1083–1087. doi: 10.1016/0016-5085(95)90206-6. [DOI] [PubMed] [Google Scholar]
  20. Logan R. F., Little J., Hawtin P. G., Hardcastle J. D. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ. 1993 Jul 31;307(6899):285–289. doi: 10.1136/bmj.307.6899.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lynch H. T., Thorson A. G., Smyrk T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer. 1995 Feb 15;75(4):936–938. doi: 10.1002/1097-0142(19950215)75:4<936::aid-cncr2820750407>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  22. Lynch N. R., Salomon J. C. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst. 1979 Jan;62(1):117–121. [PubMed] [Google Scholar]
  23. Moorghen M., Ince P., Finney K. J., Sunter J. P., Appleton D. R., Watson A. J. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol. 1988 Dec;156(4):341–347. doi: 10.1002/path.1711560411. [DOI] [PubMed] [Google Scholar]
  24. Niv Y., Fraser G. M. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology. 1994 Sep;107(3):854–857. doi: 10.1016/0016-5085(94)90136-8. [DOI] [PubMed] [Google Scholar]
  25. Northway M. G., Scobey M. W., Cassidy K. T., Geisinger K. R. Piroxicam decreases postirradiation colonic neoplasia in the rat. Cancer. 1990 Dec 1;66(11):2300–2305. doi: 10.1002/1097-0142(19901201)66:11<2300::aid-cncr2820661108>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  26. Nugent K. P., Farmer K. C., Spigelman A. D., Williams C. B., Phillips R. K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993 Dec;80(12):1618–1619. doi: 10.1002/bjs.1800801244. [DOI] [PubMed] [Google Scholar]
  27. Panje W. R. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol. 1981 Nov;107(11):658–663. doi: 10.1001/archotol.1981.00790470006003. [DOI] [PubMed] [Google Scholar]
  28. Parker A. L., Kadakia S. C., Maccini D. M., Cassaday M. A., Angueira C. E. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol. 1993 Jan;88(1):93–94. [PubMed] [Google Scholar]
  29. Pasricha P. J., Bedi A., O'Connor K., Rashid A., Akhtar A. J., Zahurak M. L., Piantadosi S., Hamilton S. R., Giardiello F. M. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 1995 Sep;109(3):994–998. doi: 10.1016/0016-5085(95)90411-5. [DOI] [PubMed] [Google Scholar]
  30. Powles T. J., Clark S. A., Easty D. M., Easty G. C., Neville A. M. The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer. 1973 Oct;28(4):316–321. doi: 10.1038/bjc.1973.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Prioleau J., Schnitt S. J. p53 antigen loss in stored paraffin slides. N Engl J Med. 1995 Jun 1;332(22):1521–1522. doi: 10.1056/NEJM199506013322217. [DOI] [PubMed] [Google Scholar]
  32. Purdie C. A., O'Grady J., Piris J., Wyllie A. H., Bird C. C. p53 expression in colorectal tumors. Am J Pathol. 1991 Apr;138(4):807–813. [PMC free article] [PubMed] [Google Scholar]
  33. Rao C. V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., Reddy B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995 Apr 1;55(7):1464–1472. [PubMed] [Google Scholar]
  34. Rao C. V., Tokumo K., Rigotty J., Zang E., Kelloff G., Reddy B. S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 1991 Sep 1;51(17):4528–4534. [PubMed] [Google Scholar]
  35. Reddy B. S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 1987 Oct 15;47(20):5340–5346. [PubMed] [Google Scholar]
  36. Reddy B. S., Nayini J., Tokumo K., Rigotty J., Zang E., Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 1990 May 1;50(9):2562–2568. [PubMed] [Google Scholar]
  37. Reddy B. S., Rao C. V., Rivenson A., Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993 Aug;14(8):1493–1497. doi: 10.1093/carcin/14.8.1493. [DOI] [PubMed] [Google Scholar]
  38. Reddy B. S., Tokumo K., Kulkarni N., Aligia C., Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis. 1992 Jun;13(6):1019–1023. doi: 10.1093/carcin/13.6.1019. [DOI] [PubMed] [Google Scholar]
  39. Rigau J., Piqué J. M., Rubio E., Planas R., Tarrech J. M., Bordas J. M. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med. 1991 Dec 15;115(12):952–954. doi: 10.7326/0003-4819-115-12-952. [DOI] [PubMed] [Google Scholar]
  40. Shiff S. J., Qiao L., Tsai L. L., Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995 Jul;96(1):491–503. doi: 10.1172/JCI118060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Skinner S. A., Penney A. G., O'Brien P. E. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg. 1991 Sep;126(9):1094–1096. doi: 10.1001/archsurg.1991.01410330048007. [DOI] [PubMed] [Google Scholar]
  42. Spagnesi M. T., Tonelli F., Dolara P., Caderni G., Valanzano R., Anastasi A., Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology. 1994 Feb;106(2):362–366. doi: 10.1016/0016-5085(94)90593-2. [DOI] [PubMed] [Google Scholar]
  43. Strausser H. R., Humes J. L. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in balb/c mice. Int J Cancer. 1975 May 15;15(5):724–730. doi: 10.1002/ijc.2910150503. [DOI] [PubMed] [Google Scholar]
  44. Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
  45. Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
  46. Waddell W. R., Ganser G. F., Cerise E. J., Loughry R. W. Sulindac for polyposis of the colon. Am J Surg. 1989 Jan;157(1):175–179. doi: 10.1016/0002-9610(89)90442-x. [DOI] [PubMed] [Google Scholar]
  47. Waddell W. R., Gerner R. E. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol. 1980;15(1):85–90. doi: 10.1002/jso.2930150113. [DOI] [PubMed] [Google Scholar]
  48. Waddell W. R., Loughry R. W. Sulindac for polyposis of the colon. J Surg Oncol. 1983 Sep;24(1):83–87. doi: 10.1002/jso.2930240119. [DOI] [PubMed] [Google Scholar]
  49. Waddell W. R., Miesfeld R. L. Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. J Surg Oncol. 1995 Apr;58(4):252–256. doi: 10.1002/jso.2930580411. [DOI] [PubMed] [Google Scholar]
  50. Waddell W. R. The effect of sulindac on colon polyps: circumvention of a transformed phenotype--a hypothesis. J Surg Oncol. 1994 Jan;55(1):52–55. doi: 10.1002/jso.2930550114. [DOI] [PubMed] [Google Scholar]
  51. Winde G., Gumbinger H. G., Osswald H., Kemper F., Bünte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis. 1993 Mar;8(1):13–17. doi: 10.1007/BF00341270. [DOI] [PubMed] [Google Scholar]
  52. Winde G., Schmid K. W., Schlegel W., Fischer R., Osswald H., Bünte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum. 1995 Aug;38(8):813–830. doi: 10.1007/BF02049838. [DOI] [PubMed] [Google Scholar]
  53. Yukawa M., Fujimori T., Maeda S., Tabuchi M., Nagasako K. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut. 1994 Sep;35(9):1258–1261. doi: 10.1136/gut.35.9.1258. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES